Isatuximab Extends Survival When Used with Carfilzomib and Dexamethasone in Multiple Myeloma
Posted: May 19, 2020
Isatuximab Extends Survival When Used with Carfilzomib and Dexamethasone in Multiple Myeloma image

Adding isatuximab to a combination with carfilzomib and dexamethasone significantly extended remission and survival for relapsed myeloma patients, according to results from the Phase III IKEMA trial. 

The trial included 302 patients with relapsed myeloma from 69 centers in 16 countries. All study participants had 1-3 prior myeloma therapies. One group received IV isatuximab (Sarclisa) once weekly for four weeks, then overy other week in combination with twice weekly carfilzomib and dexamethasone. 

The other group received twice weekly carfilzomib and dexamethasone alone. The study was to determine overall response, the level of response, MRD status, and overall survival and safety. More data is anticipated as part of upcoming medical meetings. 

Sarclisa is a monoclonal antibody targeting CD38 and is now FDA approved to be used with pomalidomide and dexamethasone. Additional approvals are anticipated and we are happy to have yet another approved drug for use by myeloma patients. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811